Showing 5741-5750 of 7683 results for "".
- National Rosacea Society Awards 2023 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2023-research-grants/2462117/The National Rosacea Society (NRS) has announced that it will contribute funding for one new study, continue funding for two ongoing studies, as part of its grant program to advance rosacea research. "Ongoing research into the pathologic processes of rosacea has ena
- Ventyx Biosciences Halts Trial for Experimental Psoriasis Drughttps://practicaldermatology.com/news/ventyx-biosciences-halts-trial-for-experimental-psoriasis-drug/2462116/Ventyx Biosciences has announced it is halting development of an experimental psoriasis drug due to missed internal targets required for it to advance beyond Phase 2, according to the company. The drug, VTX958, had shown acceptable safety and efficacy, and had achevied with its 225 mg B
- Study: Gene Expression Test IDs Best Patients for Adjuvant Radiation Therapyhttps://practicaldermatology.com/news/study-gene-expression-test-ids-best-patients-for-adjuvant-radiation-therapy/2462130/New research suggests that a 40-gene expression profile (40-GEP) test can help identify the best patients for adjuvant radiation therapy for cutaneous squamous cell carcinoma (cSCC). The study, whose results were presented at ASDS 2023, consisted of two merged validation cohorts f
- Exploring the Sunscreen Paradoxhttps://practicaldermatology.com/news/exploring-the-sunscreen-paradox/2462101/Sunscreen use may provide people with a false sense of security. The so-called sunscreen paradox suggests that individuals with higher levels of sun exposure also tend to use more but not an adequate quantity of sunscreen or other sun-protection measures, providing a false sense of
- Study: Dupilumab Shows Acceptable Long-term Safety Profile for ADhttps://practicaldermatology.com/news/study-dupilumab-shows-acceptable-safety-profile/2462097/Results from a five-year analysis suggested that long-term dupilumab for the treatment of moderate-to-severe atopic dermatitis (AD) in adults is safe and consistent with other placebo-controlled trials.
- New Insights on the Genetic Link Between Skin Tone and Ancestral Originhttps://practicaldermatology.com/news/new-insights-on-the-genetic-link-between-skin-tone-and-ancestral-origin/2462096/The link between skin pigmentation and ethnicity is more complicated than previously believed, according to new research published in the journal eLife. The team has confirmed that genes associated with East Asian and Native American anc
- Meet Sentient’s Newest Executives...https://practicaldermatology.com/news/meet-sentients-newest-executives/2462094/Brian Kirk is Sentient’s new Chief Marketing Officer (CMO), and Jennifer Redmond joins as Chief Revenue Officer (CRO). Mr. Kirk is charged with elevating Sentient's marketing investment to support Tixel by Sentient and Sentient Sculpt, while advancing the
- UCSF's HS PROGRESS Aims to Shed Light on Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucsfs-hs-progress-aims-to-shed-light-on-hidradenitis-suppurativa/2462092/University of California-San Francisco (UCSF) is leading HS PROGRESS (Hidradenitis Suppurativa [HS] Prospective Observational Registry and bioSpecimen repoSitory), a multicenter, longitudinal study that aims to comprehensively characterize HS from clinical and biological perspectives. <
- Almirall Seeks Proposals to Better Understand Key Pathological Mechanisms of Skin Diseaseshttps://practicaldermatology.com/news/almirall-seeks-proposals-to-better-understand-key-pathological-mechanisms-of-skin-diseases/2462090/Almirall S.A. is calling for proposals to better understand key pathological mechanisms of several skin diseases through AlmirallShare, its open innovation platform. Almirall’s objective through this call is to identify and explore, through collaboration w
- TREMFYA (Guselkumab) Improves PsO Symptoms Across All Skin Toneshttps://practicaldermatology.com/news/tremfya-guselkumab-improves-pso-symptoms-across-all-skin-tones/2462086/TREMFYA demonstrated significant skin clearance, rapid scalp psoriasis clearance and improvement in health-related quality of life outcomes in psoriasis patients across all skin tones, according to results from Cohort A of the VISIBLE trial. This study, which was presented at the